Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 28Lymphoma 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Breast Neoplasms 22Multiple Myeloma 21Lymphoma, Large B-Cell, Diffuse 21Carcinoma, Non-Small-Cell Lung 21Lymphoma, Non-Hodgkin 19Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hodgkin Disease 15Lymphoma, T-Cell, Cutaneous 13Glioblastoma 13Leukemia, Lymphocytic, Chronic, B-Cell 12Brain Neoplasms 12Recurrence 11Neuroblastoma 11Myelodysplastic Syndromes 11Mycosis Fungoides 11Lymphoma, B-Cell, Marginal Zone 11Leukemia 11Burkitt Lymphoma 11Neoplasms 10Sezary Syndrome 9Congenital Abnormalities 9Prostatic Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Squamous Cell Carcinoma of Head and Neck 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms, Plasma Cell 7

Interventions

Cyclophosphamide 14fludarabine 9fludarabine phosphate 8Busulfan 5Bendamustine Hydrochloride 5Tacrolimus 4Rituximab 4Mycophenolic Acid 4ibrutinib 3Melphalan 3Bortezomib 3AP 1903 reagent 3tetulomab tetraxetan lu-177 2ponatinib 2pembrolizumab 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Lutetium 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2Bone Marrow Transplantation 2thymoglobulin 1pimonidazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immune System Diseases × Vorinostat × Clear all
NCT03713320 2022-04-08

SOLAR

miRagen Therapeutics, Inc.

Phase 2 Terminated
37 enrolled 23 charts
DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Merck Sharp & Dohme LLC

Phase 3 Completed
637 enrolled 15 charts
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡